Clinical-stage nanozyme company, pioneering a first-in-human modality promising to become the next-generation anti-inflammatory medication for acute and chronic inflammatory diseases. Our lead candidate, CX213, has received FDA ODD (Orphan Drug Designation) for SAH-induced inflammation, and U.S. Phase 1 clinical study has been completed, with top-line safety data available, and the Clinical Study Report (CSR) is expected in January 2026. Our second pipeline, CX301, targeting AKI (acute kidney injury), is also advancing toward the clinic, with IND submission expected in the first half of 2026.